New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT01880567
Summary
This study is testing a combination of two drugs, ibrutinib and rituximab, for people with mantle cell lymphoma, a type of blood cancer. It is for two groups: those whose cancer has returned or hasn't responded to prior treatment, and older patients newly diagnosed with the disease. The goal is to see how well the combination works to control the cancer and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.